GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gyre Therapeutics Inc (NAS:GYRE) » Definitions » ROC %

Gyre Therapeutics (Gyre Therapeutics) ROC % : 37.91% (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Gyre Therapeutics ROC %?

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Gyre Therapeutics's annualized return on capital (ROC %) for the quarter that ended in Dec. 2023 was 37.91%.

As of today (2024-06-09), Gyre Therapeutics's WACC % is 10.43%. Gyre Therapeutics's ROC % is 37.91% (calculated using TTM income statement data). Gyre Therapeutics generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases.


Gyre Therapeutics ROC % Historical Data

The historical data trend for Gyre Therapeutics's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gyre Therapeutics ROC % Chart

Gyre Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
ROC %
49.12 8.68 37.91

Gyre Therapeutics Semi-Annual Data
Dec21 Dec22 Dec23
ROC % 49.12 8.68 37.91

Gyre Therapeutics ROC % Calculation

Gyre Therapeutics's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2023 is calculated as:

ROC % (A: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2022 ) + Invested Capital (A: Dec. 2023 ))/ count )
=19.213 * ( 1 - -11.06% )/( (48.641 + 63.92)/ 2 )
=21.3379578/56.2805
=37.91 %

where

Gyre Therapeutics's annualized Return on Capital (ROC %) for the quarter that ended in Dec. 2023 is calculated as:

ROC % (Q: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2022 ) + Invested Capital (Q: Dec. 2023 ))/ count )
=19.213 * ( 1 - -11.06% )/( (48.641 + 63.92)/ 2 )
=21.3379578/56.2805
=37.91 %

where

Note: The Operating Income data used here is one times the annual (Dec. 2023) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Gyre Therapeutics  (NAS:GYRE) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Gyre Therapeutics's WACC % is 10.43%. Gyre Therapeutics's ROC % is 37.91% (calculated using TTM income statement data). Gyre Therapeutics generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases.


Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Gyre Therapeutics ROC % Related Terms

Thank you for viewing the detailed overview of Gyre Therapeutics's ROC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Gyre Therapeutics (Gyre Therapeutics) Business Description

Comparable Companies
Traded in Other Exchanges
Address
12770 High Bluff Drive, Suite 150, San Diego, CA, USA, 92130
Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.

Gyre Therapeutics (Gyre Therapeutics) Headlines